T. Rowe Price Funds SICAV - Global Focused Growth Equity Fund Q1 USDRegister to Unlock Ratings |
Performance History | 30/09/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | 10.8 | -20.0 | 19.5 | 12.7 | |
+/-Cat | - | -3.8 | -1.9 | 3.5 | 3.3 | |
+/-B’mrk | - | -7.3 | -1.0 | -2.8 | -1.7 | |
Category: Global Large-Cap Growth Equity | ||||||
Category Benchmark: Morningstar Gbl Growth TME ... |
Key Stats | ||
NAV 30/10/2024 | USD 12.79 | |
Day Change | -0.97% | |
Morningstar Category™ | Global Large-Cap Growth Equity | |
ISIN | LU2252236455 | |
Fund Size (Mil) 30/10/2024 | USD 4119.34 | |
Share Class Size (Mil) 30/10/2024 | USD 7.86 | |
Max Initial Charge | - | |
Ongoing Charge 24/10/2024 | 0.71% |
Investment Objective: T. Rowe Price Funds SICAV - Global Focused Growth Equity Fund Q1 USD |
To increase the value of its shares, over the long term, through growth in the value of its investments. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
David Eiswert 01/10/2012 | ||
Nabil Hanano 01/01/2020 | ||
Inception Date 05/11/2020 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI ACWI NR USD | Morningstar Gbl Growth TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for T. Rowe Price Funds SICAV - Global Focused Growth Equity Fund Q1 USD | 30/09/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 5.89 |
Microsoft Corp | Technology | 4.08 |
Apple Inc | Technology | 4.02 |
Advanced Micro Devices Inc | Technology | 3.23 |
ConocoPhillips | Energy | 2.91 |
Increase Decrease New since last portfolio | ||
T. Rowe Price Funds SICAV - Global Focused Growth Equity Fund Q1 USD |